You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
In Nature this week: paternal age associated with de novo mutations in children, and more.
An analysis of more than 1,500 Icelandic families suggests new mutations in children born to older Moms are distinct and tend to cluster in some parts of the genome.
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.
Researchers identified truncating, psychosis-related mutations in RBM12 in a family affected by schizophrenia or other psychosis disorders.
Using extensive genetic data from an Icelandic population, researchers identified two rare variants associated with osteoarthritis and related hip replacements.
A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.